Therapeutic Decision Making in a New Drug Era in Multiple Sclerosis

B. Mark Keegan, MD, FRCP(C)


Semin Neurol. 2013;33(1):5-12. 

In This Article

Future Therapies

There are many continuing unmet therapeutic needs for MS patients. Particularly notable is the lack of convincing therapies for patients with SPMS and PPMS. High financial cost of therapies remains a major burden as does imperfect tolerability. A major question remains whether we can reliably prevent long-term MS disability with our current antiinflammatory medications; if not, will better understanding of progressive MS multiple sclerosis lead to neuroreparative, neuroprotective, or other therapies required. Regardless, the advances of the last two decades remain remarkable in furthering our knowledge about MS and its therapy.